http://orcid.org/0000-0001-7206-6111
References
- Bartlett, J. W., Morris, T. P., Stensrud, M. J., Daniel, R. M., Vansteelandt, S. K., and Burman, C. F. (2020), “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1755722.
- Chen, T. T. (2015), “Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors,” Journal of National Cancer Institute, 107, djv156, DOI: 10.1093/jnci/djv156.
- Cole, S. R., and Hernan, M. A. (2004), “Adjusted Survival Curves With Inverse Probability Weights,” Computer Methods and Programs in Biomedicine, 75, 45–49. DOI: 10.1016/j.cmpb.2003.10.004.
- Huang, B., Wei, L. J., and Ludmir, E. B. (2020), “Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value,” Journal of Clinical Oncology, 38, 2001–2002, DOI: 10.1200/JCO.19.03111.
- ICH E9(R1) (2019), “ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.
- Kong, F. H., and Slud, E. (1997), “Robust Covariate-Adjusted Logrank Tests,” Biometrika, 84, 847–862.
- Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T. T., Iacona, R., and Cross-Pharma Non-Proportional Hazards Working Group (2020), “Alternative Analysis Methods for Time to Event Endpoints Under Non-Proportional Hazards: A Comparative Analysis,” Statistics in Biopharmaceutical Research, 12, 187–198.
- Roychoudhury, S., Anderson, K. M., Ye, J., and Mukhopadhyay, P. (2019), “Robust Design and Analysis of Clinical Trials With Non-proportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group,” arXiv no. 1908.07112.
- Tian, L., Jin, H., Uno, H., Lu, Y, Huang, B., Anderson, K. M., and Wei, L. J. (2020), “On the Empirical Choice of the Time Window for Restricted Mean Survival Time,” Biometrics.